A patient described it to me like this, about six weeks in: I didn’t know other people weren’t doing that.
Doing what, I asked.
Thinking about lunch during breakfast.
The gap between what we measured and what happened
Look through the pivotal obesity trials and you will find percentage body weight change, waist circumference, blood pressure, lipids, glycaemic markers, quality-of-life instruments. All reasonable. All measurable.
None of them captures a woman telling you she drove past a drive-through for the first time in her adult life without having an argument with herself about it.
The trials were designed by people asking a legitimate question — does this drug reduce body weight and cardiometabolic risk — and they answered it. But the thing patients volunteer, unprompted, in the first five minutes of a follow-up appointment, is almost never the weight. It is the quiet.
We ran the largest obesity drug trials in history and did not think to ask whether people stopped thinking about food.
What it is, mechanistically, as far as anyone can say
GLP-1 receptors are not only in the gut. They are in the hypothalamus and the brainstem, and there is evidence of involvement in mesolimbic pathways associated with reward and motivation.
The plausible account is that these drugs act on the anticipatory, motivational component of eating rather than only the satiety component. You do not become full faster in a mechanical sense so much as the pull toward the next meal loses its grip.
That would also account for the odder observations attached to this class — the reduced alcohol consumption, the reports of decreased interest in nicotine and, anecdotally, in other compulsive behaviours. These are areas of active research and the causal story is genuinely unsettled. Anyone presenting it as established is ahead of the evidence.
What its absence does to people
Here is the part that surprised me most in practice: relief is not the only reaction.
Some people grieve.
If a substantial fraction of your daily mental bandwidth has been occupied by food for thirty years — the planning, the guilt, the reward, the accounting — and it disappears in a fortnight, what fills the space is not automatically pleasant. Several patients have described a flatness in the first months. One told me she had not realised how much of her social life was scaffolded around anticipating meals, and that dinners with friends now felt like watching a film with the sound off.
This is not a reason to avoid the drug. It is a reason to expect it, and to have something to say when it happens rather than treating it as an unexpected complication.
For some people the silence is not purely a relief. Food was doing emotional work, and removing it removes a coping mechanism along with the noise — which is a large part of what people describe as mood change on a GLP-1.
The maintenance problem hiding inside this
The return of food noise on discontinuation is, in my experience, the thing that distresses people most — more than the regain, and long before the regain is visible.
It arrives fast. Patients who have been off for two weeks describe it as a switch flipping back. And it lands on someone who has spent a year believing something had fundamentally changed about them.
That framing is the danger. If you understand the quiet as the drug is working, an interruption is an interruption. If you understand it as I have finally become a person who doesn’t think about food, the return is an identity collapse.
I now say this to every patient at the first appointment, before anything else has happened: the quiet is pharmacological. Enjoy it, use it, build habits inside the space it gives you — and do not mistake it for a personality transplant.
I also ask people to score it. One number a day, one to ten, for how loud food has been. Crude, unvalidated, and enormously better than nothing — it gives you something concrete to look at during an interruption, when you are certain everything has come undone, and it occasionally shows that the noise had been climbing for a fortnight before you consciously noticed. Zenday will hold a score like that next to the dose, which is the only place it carries any meaning.
What we should be doing
Measuring it. Properly, with a validated instrument, in every trial from here forward.
Because if it turns out that the reduction in intrusive food thoughts is the mechanism through which these drugs work — rather than a pleasant side effect of them working — then a great deal of how we select patients, judge response, and design the next generation is currently being decided without the most important variable in the room.